Quick Answer
OnKure Therapeutics, Inc. reported Cash and Equivalents of $59.05 million for fiscal year 2025.
OnKure Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $59.05M | -46.7% |
| 2024 | $110.76M | +270.7% |
| 2023 | $29.88M | +49.9% |
| 2022 | $19.93M | -84.0% |
| 2021 | $124.66M | +132.5% |
| 2020 | $53.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.33M | +15.9% | -15.6% |
| June 30, 2025 | $83.37M | +131.8% | -13.7% |
| March 31, 2025 | $96.66M | +374.4% | -12.7% |
| December 31, 2024 | $110.76M | +300.8% | +82.5% |
| September 30, 2024 | $60.69M | +417.1% | +68.7% |
| June 30, 2024 | $35.97M | +296.1% | +76.5% |
| March 31, 2024 | $20.38M | -33.0% | -26.3% |
| December 31, 2023 | $27.63M | +38.7% | +135.4% |
- OnKure Therapeutics, Inc. showed a decrease of -46.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, OnKure Therapeutics, Inc.’s cash and equivalents has grown by 10.1% (from $53.61 million to $59.05 million).
- The most recent figure is from OnKure Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: